HomeProductsUbrogepant
Chemical structure of CAS 1374248-77-7

Ubrogepant

CAS No.1374248-77-7
MDL No.MFCD28386182
MFC29H26F3N5O3
MW549.50
InChI KeyDDOOFTLHJSMHLN-ZQHRPCGSSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Ubrogepant is an oral CGRP receptor antagonist used for the acute treatment of migraine, with or without aura.

CAS No.1374248-77-7
Product NameUbrogepant

Biological Targets

CALCRL

Associated Conditions

migraine disorder
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor.

The Journal of pharmacology and experimental therapeutics • Vol. 373, Issue 1 • 2020
PMID: 31992609DOI: 10.1124/jpet.119.261065

Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries.

Cephalalgia : an international journal of headache • Vol. 40, Issue 4 • 2020
PMID: 31674221DOI: 10.1177/0333102419884943

Gepants for the treatment of migraine.

Expert opinion on investigational drugs • Vol. 28, Issue 6 • 2019
PMID: 31081399DOI: 10.1080/13543784.2019.1618830

Advances in orally administered pharmacotherapy for the treatment of migraine.

Expert opinion on pharmacotherapy • Vol. 20, Issue 2 • 2019
PMID: 30475090DOI: 10.1080/14656566.2018.1549223

Documentation

Similar Products